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E-mail address: kovacs@unimelb.edu.au (S. Kovac)The involvement of the gastrointestinal hormone gastrin in the development of gastrointestinal
cancer is highly controversial. Here we demonstrate a positive-feedback loop whereby gastrin, act-
ing via the CCK2 receptor, increases its own expression. Such an autocrine loop has not previously
been reported for any other gastrointestinal hormone. Gastrin promoter activation was dependent
on the MAP kinase pathway and did not involve Sp1 binding sites or epidermal growth factor recep-
tor transactivation. As the treatment of gastrointestinal cancer cells with amidated gastrin led to
increased expression of non-amidated gastrins, the positive-feedback loop may contribute to the
sustained increase in circulating gastrins observed in colorectal cancer patients.
 2010 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Amidated gastrin (Gamide) is responsible for gastric acid secre-
tion as well as for maintenance of the integrity of the gastric
mucosa. Gastrin gene expression is regulated by acid via a
negative-feedback loop. In response to gastric antral distension,
pH elevation or contact with amino acids and peptides during a
meal, gastrin is released from antral G cells into the circulation
[1]. Gastrin then stimulates the release of gastric acid, causing
gastric pH to fall. Low pH in turn activates the release of somato-
statin, the inhibitor of gastrin release, and circulating gastrin
returns to basal levels [2].
Gamide is processed from an 80 amino acid precursor (progas-
trin) by a series of enzymatic cleavages and by transamidation [1].
There is now abundant evidence that non-amidated gastrins like
progastrin and glycine-extended gastrin (Ggly) act as growth fac-
tors for the normal colorectal mucosa, and stimulate the develop-
ment of colorectal carcinoma in animals [3–5]. A connection
between Gamide and some forms of gastric cancer is ﬁrmly estab-
lished in animal models but less clearcut in humans (reviewed by
[6,7]). All the actions of amidated gastrins are mediated via thechemical Societies. Published by E
r; EGFR, epidermal growth
e; MAPK, mitogen activated
rgery, Austin Health, Studley
9458 1650.
.cholecystokinin-2 receptor (CCK2R), but the identity of the recep-
tor(s) for non-amidated gastrins remains unknown.
In this paper we have investigated by quantitative PCR and by
luciferase reporter assay whether or not gastrin can regulate its
own expression in gastrointestinal cancer cell lines. Herein we re-
port the unexpected discovery that gastrin activates its own tran-
scription in a positive-feedback loop via the CCK2R. The resultant
increased production of non-amidated forms of gastrin (Ggly)
may explain the sustained increase in circulating gastrins in pa-
tients with colorectal cancer (CRC).
2. Materials and methods
2.1. Cell lines
The following human cell lines were used: AGS wildtype (WT),
AGS transfected with CCK2R cDNA (AGS CCK2R), Colo320 WT,
Colo320 transfected with CCK2R cDNA (Colo320 CCK2R), Lovo
and JURKAT. All cells were maintained in RPMI supplemented with
8% FBS and grown in a humidiﬁed incubator at 37 C.
2.2. Amidated and non-amidated gastrin radioimmunoassay
Region-speciﬁc gastrin antisera were used to measure amidated
gastrin (antiserum 1296) and its precursor glycine-extended gas-
trin (antiserum 7270) by radioimmunoassay as described previ-
ously [8]. The crossreactivity of antiserum 7270 for amidated
gastrin is 0.07.lsevier B.V. All rights reserved.
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The basic luciferase vector pFR-luciferase (Luc) containing
1300 bp of the human gastrin promoter region and the ﬁrst exon
of the gastrin gene (1300pFR-GASLuc) was a generous gift from
Professor J. Merchant (University of Michigan, Ann Arbor). The
1300 bp fragment was cloned into pGL3 basic vector and served
as a template for preparation of ﬁve subsequent 50-deleted gastrin
promoter constructs, retaining 1147, 948, 666, 365 or 109 bp of the
promoter region as well as the ﬁrst exon. Restriction sites for Nhe I
and Bgl II were introduced at the 50 and 30 ends, respectively, of
each PCR product by polymerase chain reaction with the primers
listed in Table 1. The fragments were ligated into the Nhe I and
Bgl II sites of the pGL3 vector using T4 DNA ligase (Roche Diagnos-
tics, Castle Hill, Australia). Site-directed mutagenesis of GC boxes 1
(GGCGGG? ACTAGT) and 2 (GGCGGG? GAATTC) within the
365 bp gastrin promoter construct was performed by introduction
of unique restriction enzyme sites, SpeI and EcoRI, respectively. All
constructs were veriﬁed by sequencing (Micromon, Monash Uni-
versity, Clayton, Australia).
2.4. Transfection
Lipofectamine LTX or Lipofectamine 2000 (Invitrogen, Mel-
bourne, Australia) was used for transfection according to the man-
ufacturer’s instructions. Brieﬂy, cells were seeded at a density of
0.5–1.0  105/well in 24-well plates 16 h prior to transfection.
Cells had usually reached 70–80% conﬂuency at the time of trans-
fection and were washed once with Opti-MEM prior to the proce-
dure. Each well was transfected with 0.5–1 lg of the test plasmid
in 500 ll Opti-MEM containing 2 ll of lipofectamine reagent. After
6 h the medium was replaced with fresh RPMI medium supple-
mented with 8% FBS (1ml/well) and cells were incubated at 37 C
for a further 24-48 h before assay.
2.5. Reporter gene assay
Luciferase activity was determined using the Luciferase Assay
kit (Promega, Hawthorn, Australia). Brieﬂy, cells were lysed using
60–70 ll/well reporter lysis buffer on a shaker at room tempera-
ture for 20 min. Aliquots of 15–20 ll lysate from each sample were
distributed into wells on opaque 96-well microtitre plates and an
equal amount of LAR-II (ﬁreﬂy substrate) was added. Luciferase
activity was measured with a MicroLumi XS luminometer (Harta
Instruments, Gaithersburg, MD, USA). Luciferase activity was nor-
malised to the total protein content of each well determined using
the Bradford reagent (Bio-Rad, Gladesville, Australia).Table 1
List of primers used to produce the GASLuc constructs.
Primers Sequence (50–30)
p1,147-GASLuc forward GGGGTACCCTGTTTGCTAACCATTTGAG
p948-GASLuc forward GGGGTACCGCGCCTGTAATCCCAGCTC
p666-GASLuc forward GGGGTACCGGGCAGCTACAAGCCAAAC
p365-GASLuc forward GGGGTACCACCTACCACCACCCACAAG
GASLuc reverse – for all
gastrin promoter
constructs
GAAGATCTCTGCAGAGCTGGGAGGTG
GC Box2 mutagenesis
Forward TGGAATTCGCAGGGTGATGGGCTG
Reverse GCGAATTCCTTTCATTTATGTTCAGTCAGTCATCC
GC Box1 mutagenesis
Forward GGACTAGTGTGGGGGGACAGTTGGG
Reverse GTACTAGTCCTACCCTGCCATATGAGTCC2.6. RNA preparation and quantitative PCR of gastrin mRNA
Cells were seeded at a density of 2.5  105/well in 6-well plates
in growth media. Next day cells were treated and the following day
total RNA was isolated from cells using TRIzol reagent (Invitrogen,
Melbourne, Australia) according to the manufacturer’s instruc-
tions. Five micrograms of total RNA was used for cDNA synthesis
with the SuperscriptTM II ﬁrst strand synthesis system (Invitrogen).
The resulting cDNA transcripts of mRNA were used for real time
PCR ampliﬁcation with the ABI PRISM 7700 Sequence Detector
(Applied Biosystems, Melbourne, Australia) and Taqman chemis-
try. The following primers were used: forward 50-CCGCAGTGCT-
GAGGATGAG-30, reverse 50-GGAGGTGGCTAGGCTCTGAA-30, probe
50-CTAACAATCCTAGAACCAAG-30. Gene expression was quanti-
tated relative to 18S RNA expression.
2.7. Statistical analysis
Statistical signiﬁcance for single comparisons of normally dis-
tributed data was assessed by Student’s t-test or for data that
was not normally distributed by Mann–Whitney rank sum test.
For multiple comparisons one-way ANOVA was used. All statistics
were analysed with the statistical program SigmaStat and graphed
using SigmaPlot (Jandel Scientiﬁc, San Rafael, CA).3. Results
3.1. Gastrin activates its own transcription via the CCK2R
To determine whether or not gastrin upregulates its own
expression, gastrin mRNA was measured in a number of gastroin-
testinal cancer cell lines with and without treatment with Gamide.
In AGS CCK2R cells, gastrin gene transcription was activated by 31-
and 44-fold with 10 and 50 nM Gamide, respectively. Signiﬁcant
but smaller increases were observed in Colo320 CCK2R cells (1.5-
and 4.4-fold with 10 and 50 nM Gamide, respectively) and in JUR-
KAT cells that express endogenous CCK2R (2.5- and 3.6-fold with
10 and 50 nM Gamide, respectively). Gastrin gene transcription
was activated only in those cells that expressed the CCK2R,
whether the receptor was endogenously expressed (JURKAT) or
transfected (AGS CCK2R and Colo320 CCK2R) (Fig. 1A). When Ggly
was measured as a marker of an increase in translation of the gas-
trin gene, cell lines that expressed the CCK2R also released more
Ggly into the cell growth media following stimulation with Gamide
(Fig. 1B). Although the presence of exogenous Gamide prevented
the measurement of endogenous Gamide in conditioned media,
the detection of secreted Gamide in the media conditioned by un-
treated AGS or AGS CCK2R cells (1.7 ± 0.9 and 3.1 ± 1.4 fmol/ml,
respectively) clearly established that the peptidyl a-amidating
monooxygenase was present and capable of converting Ggly into
Gamide. The AGS CCK2R cell line was chosen for further studies be-
cause it showed the greatest increase in gastrin mRNA synthesis.
3.2. Activation of the gastrin promoter is time-dependent
The dose response and time course of gastrin transcription were
next examined. Promoter activation was measured in a luciferase
reporter assay with AGS CCK2R cells transfected with a pGL3 lucif-
erase reporter vector containing 1300 bp of the human gastrin pro-
moter. Promoter activity increased following the addition of 10, 50
or 100 nM of Gamide (Fig. 2A), and a concentration of 50 nM was
chosen for subsequent experiments. Time course experiments indi-
cated that promoter activation was maximal at 8 h (Fig. 2B). Mea-
surement of gastrin mRNA by quantitative RT-PCR indicated that
transcription continued to increase up to at least 16 h (Fig. 2C).
Fig. 1. Gastrin increases gastrin mRNA transcription via the CCK2 receptor. (A) A number of gastrointestinal cell lines with or without CCK2 receptors were stimulated with
10 nM (grey bars) or 50 nM (black bars) Gamide for 16 h. Gastrin mRNA was subsequently measured using real time PCR and expressed relative to the amount of 18S rRNA.
The ratio was compared to the value for unstimulated cells (white bars). (B) Increased activation of gastrin mRNA transcription in AGS CCK2R, Colo320 CCK2R and JURKAT
cells by 50 nM Gamide led to increased Ggly concentrations in the conditioned medium. Data are mean ± S.E.M. (n = 3; **P < 0.01; ***P < 0.001).
Fig. 2. AGS CCK2R cells stimulated with 50 nM Gamide increase gastrin mRNA
and promoter activity in a time-dependent manner. (A) The gastrin promoter is
activated in a dose-dependent manner. Cells were treated with 1, 10, 50 and
100 nM of Gamide for 16 h. A concentration of 50 nM was chosen for subsequent
experiments. (B) Cells were treated with 50 nM Gamide for the indicated times,
and activation of the gastrin promoter was measured using luciferase reporter
assay. Ggly did not stimulate promoter activation. (C) Cells were treated with
50 nM Gamide for the indicated times, and gastrin mRNA was subsequently
measured using real time PCR and expressed relative to the amount of 18S rRNA.
The ratio was compared to the value for unstimulated cells. The time course for
activation of transcription of gastrin mRNA matched closely with the time course
for promoter activation. Data are mean ± S.E.M. (n = 3; *P < 0.05; **P < 0.01;
***P < 0.001).
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(Fig. 2B) or gastrin mRNA (data not shown).3.3. A minimal human gastrin promoter is responsible for the
activation of the gastrin gene
To identify the regions of the human gastrin promoter required
for activation by Gamide, sequential deletion mutants retaining
from 1147 to 365 bp of the human gastrin promoter were con-
structed using PCR techniques. The mutants were transfected into
AGS CCK2R cells and their basal activities assayed. All deletion con-
structs of the gastrin promoter (1147, 948, 666 and 365 bp)
showed similar increases in activity in response to Gamide treat-
ment (Fig. 3).
3.4. Gastrin activates the gastrin positive-feedback loop via the MAP
kinase pathway
To determine which signalling pathways downstream of the
CCK2R were involved in the Gamide-dependent activation of the
human gastrin promoter a panel of receptor antagonists and pro-
tein kinase inhibitors was tested. The CCK2R antagonist
(RP73870A) completely blocked Gamide-dependent promoter
activity. In addition, the speciﬁc mitogen activated protein kinase
(MAPK) inhibitor (U0126) reduced Gamide-dependent promoter
activation to control levels, while the inhibitor Sorafenib (which
targets a tyrosine kinase upstream of the MAPK pathway [9]) also
inhibited gastrin promoter activity to a similar extent. Interest-
ingly, the PI3 kinase inhibitor (Ly294002) did not inhibit Ga-
mide-dependent promoter activation (Fig. 4). The failure of T-25
(an inhibitor of the epidermal growth factor receptor (EGFR) tyro-
sine kinase) to abrogate Gamide-dependent promoter activation
suggests that the EGFR is not involved in the enhancement of gas-
trin transcription (Fig. 4).
3.5. Activation of the gastrin promoter by gastrin is Sp1-independent
To dissect further the mechanism of transcriptional activation
of the gastrin gene, known transcription factor binding sites within
the shortest active promoter construct (p365-GASLuc) were mu-
tated by site-directed mutagenesis. The observations that activa-
tion of the CCK2R leads to activation of the MAPK pathway [10–
12], and that MAPK can phosphorylate Sp1 [13], suggested that
the Sp1 elements within the human gastrin promoter (Fig. 5A)
were likely candidates. However, upon stimulation with Gamide
no differences were observed in the luciferase activity between
the mutated and wild-type gastrin promoter constructs (Fig. 5B).
Fig. 3. Comparison of promoter activities following Gamide treatment in AGS CCK2R cells. (A) Gastrin promoter-reporter constructs with 50 deletions were constructed as
described in the Section 2. The promoter deletion constructs were individually transfected into AGS CCK2R cells. Luciferase activity of each vector was measured, normalised
to the total protein concentration, and the value expressed as a percentage of that observed for p1147-GASLuc without Gamide treatment (white bar). Promoter activity of all
constructs was increased following Gamide treatment (black bars). Data are mean ± S.E.M. (n = 3, *P < 0.05).
Fig. 4. Gastrin activates the gastrin positive-feedback loop via the MAPK pathway.
AGS CCK2R cells transfected with the shortest active fragment of the human gastrin
promoter, p365-GASLuc, were treated with a panel of receptor antagonist and
kinase inhibitors (grey bars) 30 min prior to the addition of 50 nM Gamide (black
bar). Gamide stimulation is calculated compared to unstimulated cells (white bar).
The CCK2R antagonist RP73870A, the MAPK inhibitor U0126 and the MAPK-speciﬁc
tyrosine kinase inhibitor, Sorafenib, all inhibited activation of the human gastrin
promoter in the luciferase reporter assay. The PI3K inhibitor Ly294002 and the
EGFR inhibitor T-25 had no effect on gastrin promoter activity. Data are mean ± -
S.E.M. (n = 3, *P < 0.05; **P < 0.01; ***P < 0.001).
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which contained only the proximal Sp1 site showed no reduction
in promoter activity (data not shown). Taken together the results
indicate that activation of the gastrin promoter by Gamide is
Sp1-independent.
4. Discussion
Although gastrin was discovered over 100 years ago its direct
involvement in the growth of gastrointestinal cell lines and tu-
mours remains controversial. Here we demonstrate by quantitative
PCR and by luciferase reporter assay that Gamide is able to activate
its own promoter, and hence transcription of the gastrin gene, in a
time-dependent manner. To our knowledge such a positive-feed-
back loop has not yet been linked to the mechanism of any other
gastrointestinal hormone, although interleukin-1 has been re-
ported to induce its own expression via the interleukin-1 receptor
in human mesangial cells [14]. A more usual positive-feedback
loop consists of one growth factor activating the synthesis of an-
other thus potentiating the growth signal [15]. The observationthat Gamide increases its own transcription is also in contrast to
the more common ligand-dependent repression by which gene
products prevent their own over-expression [16].
The increase in transcription of the gastrin gene also results in
increased translation. Following stimulation with Gamide cell lines
that expressed the CCK2R also released more Ggly into the cell
growth media (Fig. 1B). Unfortunately the addition of excess Ga-
mide into the media at concentrations far exceeding the amount
of Gamide produced endogenously made it impossible to measure
the relatively small increases in endogenous Gamide. However, the
fact that Gamide is produced by untreated AGS wild type and AGS
CCK2R cells clearly established that the peptidyl a-amidating
monooxygenase responsible for conversion of Ggly to Gamide is
present and active in this cell line. Thus we conclude that an in-
crease in Gamide production is also likely in response to Gamide
treatment.
The positive-feedback loop for Gamide is dependent on expres-
sion of the CCK2R. Thus cells not expressing the CCK2R did not re-
spond while in responsive cells a CCK2R antagonist completely
blocked the Gamide-dependent increase in luciferase reporter
activity. We were unable to ﬁnd gastrointestinal cell lines express-
ing endogenous CCK2 receptors to conﬁrm our ﬁndings in a non-
transfected cell line, as even Lovo cells, which have been reported
to express endogenous CCK2R [17], failed to bind gastrin in our
hands (data not shown). However, the presence of the gastrin po-
sitive-feedback loop was detected in a lymphoblastoid T cell line
(JURKAT) which is known to express endogenous CCK2R [18].
Interestingly, Gamide has also been shown to upregulate the
expression of the CCK2R [19] thereby potentiating the positive-
feedback loop.
The signalling pathways involved were investigated with spe-
ciﬁc inhibitors. One of the major signalling pathways activated
downstream of the CCK2R is the MAPK cascade [10–12]. The obser-
vation that two inhibitors of the MAPK pathway completely
blocked the Gamide-dependent increase in luciferase reporter
activity indicates that MAPK is indeed the major pathway activated
by Gamide via the CCK2R in the positive-feedback loop. In addition,
Gamide transactivates the EGFR by inducing the expression of hep-
arin-binding epidermal growth factor-like growth factor (HB-EGF)
which binds to EGFR, causing tyrosine phosphorylation of the EGFR
and subsequent activation of downstream signalling pathways
[11,20,21]. However, the observation that an EGFR inhibitor did
not prevent the Gamide-dependent promoter activation is consis-
tent with a direct effect of Gamide on the activation of its own
promoter.
Gamide stimulates the expression of genes required for acid
secretion and for cell proliferation and migration. For example
Fig. 5. Activation of the gastrin promoter by gastrin is Sp1-independent. (A) Sequence of the gastrin promoter demonstrating the location of two Sp1 sites within deletion
construct p365-GASLuc. (B) Effect of site-directed mutagenesis of the Sp1 sites in p365-GASLuc showing that the gastrin positive feedback loop is not mediated via the Sp1
sites. Data are mean ± S.E.M. (n = 3, *P < 0.05).
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genes encoding vesicular monoamine transporter type 2 [22] and
histidine decarboxylase [23]. Although no GREs were identiﬁed
within the gastrin gene, the promoter does contain a number of
Sp1 sites which are involved in activation of gastrin expression
by EGF [24]. Using sequential deletion fragments of the human
gastrin promoter, responsiveness to exogenous Gamide was shown
to lie within the proximal 365 bp of the promoter. Although this
region contains two Sp1 sites, the activation of the gastrin pro-
moter by exogenous Gamide does not appear to be mediated via
either site, since mutation of either or both Sp1 sites did not affect
Gamide responsiveness in the luciferase reporter assay.
One potentially important functional consequence of increased
gastrin gene transcription is an increased secretion of the imma-
ture forms of gastrin (Ggly) into the cell culture medium
(Fig. 1B). Hence in CRC patients the positive-feedback loop may
contribute to the increased expression of gastrin mRNA within
the tumour [25], and to the sustained increase in circulating gas-
trins [8,26,27]. The signiﬁcance of this observation is that Ggly pro-
motes the growth of various gastrointestinal cell lines [28–30], and
acts as a co-carcinogen in vivo. Thus Ggly-treated rats have in-
creased numbers of colorectal tumour precursors after treatment
with azoxymethane [3], and polyp numbers were increased in
APCmin/+ mice overexpressing Ggly [31].
Hypergastrinemia is a well known consequence of the increased
use of proton pump inhibitors (PPI) to treat both acid secretory dis-
orders and Helicobacter pylori infections. Although increased circu-
lating Gamide causes gastric ECL hyperplasia in rats and synergises
with H. pylori infection in mouse models of gastric adenocarci-
noma, and both effects are mediated via the CCK2R, the general
consensus is that Gamide does not contribute to the development
of gastric neuroendocrine tumours or adenocarcinomas in humans
[7]. Interestingly, therapy for 5 years or longer with high, but not
low, dose PPIs is strongly correlated with an increased incidence
of CRC [32]. The CCK2R, although not often expressed on CRC tu-
mour cells [33], is found on polymorphs within the tumour stroma
[34]. The data presented herein are consistent with the suggestion
that PPI-induced hypergastrinemia may accelerate the develop-
ment of CRC indirectly by stimulating the expression of non-ami-
dated gastrins by such CCK2R-expressing polymorphs. Thus the
regulation of the gastrin positive-feedback loop by hypergastrin-
emia and its role in CRC development clearly warrants further
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